← All trials
NCT04975958
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 7, 2021
- Primary completion
- Dec 31, 2021
- Completion date
- Nov 30, 2022
- First posted
- Jul 26, 2021
- Last posted
- Nov 17, 2021
- Enrollment
- 63
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Adlai Nortye Biopharma Co., Ltd.Lead sponsor
- Adlai Nortye Biopharma Co., Ltd.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.